Eli Lilly

Eli Lilly and Company (LLY) – New Diabetes drug to drive future growth

in , , on December 22, 2022

This report is useful for M&A and business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms, and corporates to decide upon their investment strategies. Do connect with us, if you are looking for insights on any specific sector/industry and market recommendations.

Eli Lilly and Company (LLY)

Eli Lilly and Company experienced significant performance in the quarter which was driven by a higher volume of drugs sold. Lilly’s revenue increased by 7% on a constant currency basis, primarily driven by the volume growth of key growth products.



– Enterprise Value
– CrispIdea Forecast
– Economic Value-Added Analysis
– Discounted Cash Flow Analysis
– PE Band Comparison
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10-Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance


Stock Price Performance

Crispidea Coverage

No of Pages: 34

Release Information

  • Price


  • Released

    December 22, 2022

  • Last Updated

    December 29, 2022